A 72-year-old man with benign prostatic hyperplasia and a prostate volume of 55 mL on ultrasound presents with persistent lower urinary tract symptoms despite 3 months of tamsulosin monotherapy. His PSA is 6.2 ng/mL and post-void residual remains 95 mL. He is normotensive and has no cardiac comorbidities. What is the most appropriate next pharmacological step?

## Combination Therapy for BPH: α1-Blocker + 5-Alpha Reductase Inhibitor **Key Point:** When monotherapy with an α1-blocker fails after adequate trial (≥3 months), combination therapy with a 5-alpha reductase inhibitor (finasteride or dutasteride) is the next pharmacological step, particularly in men with larger prostate glands (>40 g). ### Clinical Rationale for Combination Therapy This patient has: - **Large prostate volume** (55 mL = 55 g, well above the 40 g threshold) - **Inadequate response to α1-blocker monotherapy** after 3 months - **Elevated PSA** (6.2 ng/mL, suggesting significant glandular tissue) - **Persistent PVR** (95 mL, borderline for intervention) ### Mechanism of Combination Approach | Drug Class | Mechanism | Timeline | Indication | |-----------|-----------|----------|------------| | **α1-Blocker (tamsulosin)** | Smooth muscle relaxation; rapid symptom relief | 2–3 weeks | All symptomatic BPH | | **5-α Reductase Inhibitor (finasteride)** | Blocks DHT; reduces prostate volume | 6–12 months | Large glands (>40 g); elevated PSA; failure of monotherapy | | **Combination** | Rapid relief + long-term gland shrinkage | 6–12 months for full benefit | Large glands + inadequate monotherapy response | **High-Yield:** The **MTOPS trial** (Medical Therapy of Prostatic Symptoms) demonstrated that combination therapy with doxazosin + finasteride was superior to monotherapy in reducing symptom progression and acute urinary retention in men with large prostate glands and elevated PSA. ### Why Finasteride is Added Now 1. **Prostate volume >40 g:** Finasteride is most effective in large glands; expected volume reduction of 20–30% over 6–12 months. 2. **Monotherapy failure:** Indicates need for additional mechanism (volume reduction, not just smooth muscle relaxation). 3. **Elevated PSA:** Suggests significant epithelial hyperplasia responsive to DHT inhibition. 4. **Symptom progression risk:** Combination therapy reduces risk of acute retention and need for surgery. **Clinical Pearl:** Finasteride takes 6–12 months to show maximal benefit; the patient should be counseled to continue tamsulosin for immediate symptom control while finasteride reduces gland volume over time. PSA will drop by ~50% with finasteride; this is expected and not concerning. **Mnemonic:** **LARGE + FAIL = ADD 5-ARI** — Large prostate (>40 g) + Failed monotherapy = Add 5-Alpha Reductase Inhibitor. [cite:Harrison 21e Ch 305; Robbins 10e Ch 20]